SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as investors weigh its potential following recent partnerships and discussions around AI infrastructure build-out. Community members are actively debating the impact of these partnerships on revenue, the company's management, and potential accounting concerns. Additionally, discussions involve potential short squeezes and comparisons to other trending stocks in the AI sector.

CaliberCos, Inc. operates as an asset management firm. It provides various support services including asset management & fund set-up services, as well as lending support, construction & development management, and real estate brokerage services. The company was founded by John Christopher Loeffler II and Jennifer Schrader in January 2009 and is headquartered in Scottsdale, AZ.

CaliberCos Inc - Ordinary Shares - Class A

CaliberCos Inc 

CaliberCos ($CWD) is trending due to a massive pre-market surge following news of its initial purchase of Chainlink tokens as part of a digital asset treasury strategy, mirroring the recent frenzy around $OCTO. Community chatter revolves around whether it will maintain momentum or experience a significant pullback, while others are looking for the next similar play. Some traders are also discussing shorting the stock after the massive run-up.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending after securing a significant AI infrastructure deal with Microsoft, causing community excitement and discussion around potential revenue growth and future partnerships.  Many believe the stock is undervalued given the size of the contract relative to its market cap, leading to speculation about target prices and potential short squeezes. The conversation also includes comparing NBIS to competitors and analyzing the broader AI and data center sector.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as positive Medicare Advantage Star Ratings data is fueling optimism and a potential squeeze, with community members eyeing a gap fill. Some traders are speculating about a possible investigation case being dropped or positive news leaked. The stock's recent performance has bulls celebrating and bears running for cover, while many anticipate further gains.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending after showcasing its solid-state batteries powering a Ducati motorcycle, marking a significant step from lab to real-world application, though some express concern over timeline to commercialization. The community is buzzing about the implications of this milestone, particularly its potential to attract further partnerships and disrupt the EV battery landscape. While some traders are wary of a potential pullback, long-term investors see validation of the technology and its potential for high-performance vehicles.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

QMMM Holdings Ltd. engages in the provision of digital advertising services. It offers interactive design, animation, art-tech and virtual technologies used in commercial campaigns. It has worked with domestic and international banks, real estate developers, amusement parks, international sports apparel, footwear brands, luxury cosmetic products, and international brands. The company was founded by Bun Kwai on July 29, 2022 and is headquartered in Hong Kong.

QMMM Holdings Ltd. - Ordinary Shares - Class A

QMMM Holdings Ltd.

StableX Technologies, Inc. engages in the design, development, manufacture, and sale of compact electric fleet solutions for use within urban and short-haul markets. It offers the AYRO 311 and Club Car 411 models. The company was founded on May 19, 2016 and is headquartered in New York, NY.

StableX Technologies Inc.

StableX Technologies, Inc. 

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty

Investing.com -- TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, following a Complete Response Letter from the U.S. Food and Drug Administration.The FDA issued a Complete Response Letter for MIST’s etripamil New Drug Application for paroxysmal supraventricular tachycardia (pSVT), citing chemistry, manufacturing, and controls issues. While no safety or efficacy concerns were raised, the agency requested additional data on nitrosamine impurities based on new draft guidance published in September 2024, months after MIST had resubmitted its New Drug Application . The FDA also flagged the need for an inspection at a third-party facility performing release testing, which changed ownership during the New Drug Application review.

Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/03/28/3051260/0/en/FDA-Issues-Complete-Response-Letter-for-Etripamil-for-PSVT.html">not approve</a> its lead investigational product, Cardamyst.The nasal spray is under development to treat episodes of abnormal heart rhythm associated with Paroxysmal supraventricular tachycardia (PSVT).The FDA highlighted two key Chemistry, Manufacturing and Controls (CMC) issues.The regulator asked the company to submit additional information on nitrosamine impurities based on the new draft guidance issued after the New Drug Application (NDA) submission. &nbsp;The agency also said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.Milestone Pharmaceuticals CEO Joe Oliveto said that the company is “deeply disappointed” by the letter but remains committed to the potential of the drug in treating patients with PSVT.“Our team is evaluating the feedback provided and intends to request a Type A meeting to discuss the issues raised in the CRL,” Oliveto said. “We are appreciative of the FDA’s efforts and are confident we can collaborate with the agency with the goal of addressing these issues in a resubmission.”The FDA did not raise any concerns regarding the drug’s clinical safety or efficacy, the company said.The nasal spray has been designed as a self-administered rapid response therapy, thereby bypassing the need for immediate medical oversight, it explained.On Stocktwits, retail investor sentiment about Milestone Pharmaceuticals dropped slightly within the ‘extremely bullish’ territory (89/100), while message volume remained at ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:652/152;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_28_at_12_10_06_PM_png_e7518f6d31.webp" alt="MIST's Sentiment Meter and Message Volume as of 12:10 p.m. ET on March 28, 2025 | Source: Stocktwits" width="652" height="152"><figcaption>MIST's Sentiment Meter and Message Volume as of 12:10 p.m. ET on March 28, 2025 | Source: Stocktwits</figcaption></figure>Following the company’s announcement, HC Wainwright kept a ‘Buy’ rating on Milestone pharmaceuticals and noted that the FDA flagged no concerns around the efficacy of the product, thereby reaffirming the integrity of the clinical data.However, the firm expects the product's launch to be delayed until the first half of 2026.<a href="https://stocktwits.com/symbol/MIST">Shares of Milestone Pharmaceuticals</a> fell over 55% this year and by over 45% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/hyperscale-data-shares-drop-despite-completing-first-nvidia-gpu-installation/chJ3iDORbEC">Hyperscale Data Stock Drops Despite Completing First Nvidia GPU Installation – But Retail Turns Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive 

The FDA said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.

Equity

Milestone Pharmaceuticals Upgraded to Buy: Here's What You Should Know

Milestone Pharmaceuticals (NASDAQ: MIST) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings...

Milestone  Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company...

Milestone  Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...

Milestone's Etripamil Aims to Revolutionize PSVT Treatment

Milestone Pharmaceuticals (MIST) has released an update. Milestone Pharmaceuticals has announced the resubmission of its New Drug Application to th...

Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...

Milestone Pharmaceuticals (NASDAQ:MIST) Stock Rating Reaffirmed by HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST  Get Free Report)s stock had its buy rating restated by research analysts at HC Wainwright in a research note issued on Friday...

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

- On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2...

https://files.quartr.com/streams/2025-09-09/1f5f174c-40e8-4989-b57d-4086fbc53754/1/live_transcript.jsonl?ref=U3RvY2t0d2l0cw==

Milestone Pharmaceuticals Inc

H.C. Wainwright 27th Annual Global Investment Conference

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with $NBIS stock after its $17.4 billion AI infrastructure deal with $MSFT?

Stocktwits

Microsoft Corp

 stock after its $17.4 billion AI infrastructure deal with 

MIST
Milestone Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MIST News

MIST Milestone Pharmaceuticals Inc